Yueyin Pan

机构：University of Science and Technology of China, Anhui Provincial Hospital · ORCID：0009-0006-8274-8902

发表论文 47 篇 · 总被引 425 次 · h-index 13

代表论文

• Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer (2024 · JAMA Oncology · 被引 62)
• CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial (2025 · Nature Medicine · 被引 40)
• Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: A phase 1 dose escalation and expansion study. (2024 · Journal of Clinical Oncology · 被引 21)
• Safety and efficacy of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with advanced pancreatic ductal adenocarcinoma: Preliminary results from a phase 1 study. (2024 · Journal of Clinical Oncology · 被引 19)
• Safety and efficacy of IBI343 (anti-claudin18.2 antibody-drug conjugate) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer: Preliminary results from a phase 1 study. (2024 · Journal of Clinical Oncology · 被引 19)
• Hetrombopag for the management of chemotherapy-induced thrombocytopenia in patients with advanced solid tumors: a multicenter, randomized, double-blind, placebo-controlled, phase II study (2024 · Therapeutic Advances in Medical Oncology · 被引 13)